Literature DB >> 21924246

Cytotoxicity and cell death mechanisms induced by the polyamine-vectorized anti-cancer drug F14512 targeting topoisomerase II.

Viviane Brel1, Jean-Philippe Annereau, Stéphane Vispé, Anna Kruczynski, Christian Bailly, Nicolas Guilbaud.   

Abstract

The polyamines transport system (PTS) is usually enhanced in cancer cells and can be exploited to deliver anticancer drugs. The spermine-conjugated epipodophyllotoxin derivative F14512 is a topoisomerase II poison that exploits the PTS to target preferentially tumor cells. F14512 has been characterized as a potent anticancer drug candidate and is currently in phase 1 clinical trials. Here we have analyzed the mechanisms of cell death induced by F14512, compared to the parent drug etoposide lacking the polyamine tail. F14512 proved to be >30-fold more cytotoxic than etoposide against A549 non-small cell lung cancer cells and triggers less but unrecoverable DNA damages. The cytotoxic action of F14512 is extremely rapid (within 3 h) and does not lead to a marked accumulation in the S-phase of the cell cycle, unlike etoposide. Interestingly, A549 cells treated with F14512 were less prone to undergo apoptosis (neither caspases-dependent nor caspases-independent pathways) or autophagy but preferentially entered into senescence. Drug-induced senescence was characterized qualitatively and quantitatively by an increased β-galactosidase activity, both by cytochemical staining and by flow cytometry. A morphological analysis by electron microscopy revealed the presence of numerous multi-lamellar and vesicular bodies and large electron-lucent (methuosis-like) vacuoles in F14512-treated cell samples. The mechanism of drug-induced cell death is thus distinct for F14512 compared to etoposide, and this difference may account for their distinct pharmacological profiles and the markedly superior activity of F14512 in vivo. This study suggests that senescence markers should be considered as potential pharmacodynamic biomarkers of F14512 antitumor activity. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21924246     DOI: 10.1016/j.bcp.2011.08.028

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

Review 1.  Methuosis: nonapoptotic cell death associated with vacuolization of macropinosome and endosome compartments.

Authors:  William A Maltese; Jean H Overmeyer
Journal:  Am J Pathol       Date:  2014-04-13       Impact factor: 4.307

Review 2.  Investigating the Anticancer Potential of Salvicine as a Modulator of Topoisomerase II and ROS Signaling Cascade.

Authors:  Dipta Dey; Mohammad Mehedi Hasan; Partha Biswas; Stavros P Papadakos; Rehab A Rayan; Sabiha Tasnim; Muhammad Bilal; Mohammod Johirul Islam; Farzana Alam Arshe; Efat Muhammad Arshad; Maisha Farzana; Tanjim Ishraq Rahaman; Sumit Kumar Baral; Priyanka Paul; Shabana Bibi; Md Ataur Rahman; Bonglee Kim
Journal:  Front Oncol       Date:  2022-06-01       Impact factor: 5.738

3.  Activity of the polyamine-vectorized anti-cancer drug F14512 against pediatric glioma and neuroblastoma cell lines.

Authors:  Pierre Leblond; Elodie Boulet; Christine Bal-Mahieu; Arnaud Pillon; Anna Kruczynski; Nicolas Guilbaud; Christian Bailly; Thierry Sarrazin; Eric Lartigau; Amélie Lansiaux; Samuel Meignan
Journal:  Invest New Drugs       Date:  2014-07-11       Impact factor: 3.850

Review 4.  From Pinocytosis to Methuosis-Fluid Consumption as a Risk Factor for Cell Death.

Authors:  Markus Ritter; Nikolaus Bresgen; Hubert H Kerschbaum
Journal:  Front Cell Dev Biol       Date:  2021-06-23

5.  Dose escalation study to evaluate safety, tolerability and efficacy of intravenous etoposide phosphate administration in 27 dogs with multicentric lymphoma.

Authors:  Pierre Boyé; François Serres; Laurent Marescaux; Juliette Hordeaux; Emmanuel Bouchaert; Bruno Gomes; Dominique Tierny
Journal:  PLoS One       Date:  2017-05-15       Impact factor: 3.240

6.  Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer.

Authors:  Alexandra Leary; Christophe Le Tourneau; Andrea Varga; Marie-Paule Sablin; Carlos Gomez-Roca; Nicolas Guilbaud; Aurelie Petain; Mariya Pavlyuk; Jean-Pierre Delord
Journal:  Invest New Drugs       Date:  2018-12-14       Impact factor: 3.850

7.  Aptamer-Driven Toxin Gene Delivery in U87 Model Glioblastoma Cells.

Authors:  Luana di Leandro; Francesco Giansanti; Sabrina Mei; Sara Ponziani; Martina Colasante; Matteo Ardini; Francesco Angelucci; Giuseppina Pitari; Michele d'Angelo; Annamaria Cimini; Maria Serena Fabbrini; Rodolfo Ippoliti
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

Review 8.  The Role and Therapeutic Potential of Macropinocytosis in Cancer.

Authors:  Zejing Qiu; Wencheng Liu; Qianru Zhu; Kun Ke; Qicong Zhu; Weiwei Jin; Shuxian Yu; Zuyi Yang; Lin Li; Xiaochen Sun; Shuyi Ren; Yanfen Liu; Zhiyu Zhu; Jiangping Zeng; Xiaoyu Huang; Yan Huang; Lu Wei; Mengmeng Ma; Jun Lu; Xiaoyang Chen; Yiping Mou; Tian Xie; Xinbing Sui
Journal:  Front Pharmacol       Date:  2022-08-15       Impact factor: 5.988

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.